Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Drug in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma
NCT04480099Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- Jul 2020
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine, azacitidine, tucidinostat, lenalidomide in peripheral T-cell lymphoma (PTCL), sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
decitabineazacitidinetucidinostatlenalidomide
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT04480099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04480099.